The visual sequence uses conceptual membrane diagrams and evidence cards. All substantive findings are also explained in the visible captions and transcript. The full explanation is burned into the video. Optional accessible English captions can also be enabled in the player.
FDA accelerated approval concerns the prescription product Forzinity for improving muscle strength in adults and children with Barth syndrome weighing at least 30 kg. It is not an approval for anti-aging or general performance enhancement. A confirmatory trial is required; approval does not validate unverified products sold under a research label.
Transcript
SS-31
SS-31, also called elamipretide, is a four-amino-acid peptide studied for its effects on mitochondria. Its story shows why a promising mechanism, an animal experiment, and a human treatment claim are different kinds of evidence.
Start with the membrane.
The central target is cardiolipin, a lipid in the inner mitochondrial membrane. Laboratory experiments found that SS-31 interacts with cardiolipin and can limit the damaging peroxidase activity of cytochrome c, a protein that normally helps transfer electrons. [1] [2] [5]
A mechanism is not a benefit.
Related experiments in isolated mitochondria found improvements in electron transport and ATP production. These findings explain a biological rationale. They do not establish a general energy boost in people. [1] [2]
Keep the model in the picture.
In a rat model of interrupted blood flow to the kidneys, pretreatment with SS-31 preserved mitochondrial membrane folds and supported recovery after blood flow returned. That is evidence from a particular injury model, not proof of human rejuvenation or longer life. [1]
Read the primary result.
In MMPOWER-3, a randomized trial involving 218 participants with primary mitochondrial myopathy, elamipretide did not significantly improve six-minute walking distance or fatigue compared with placebo after 24 weeks. Exploratory findings should not replace that overall result. [3]
The design changes the claim.
In Barth syndrome, a separate randomized crossover study of twelve participants also failed to show benefit on its primary walking and fatigue endpoints. Improvements were subsequently observed during an open-label extension, when participants knew they were receiving treatment and there was no concurrent placebo group. Those design differences matter. [4]
A specific FDA approval.
In September 2025, the FDA granted accelerated approval to Forzinity, the prescription elamipretide product, to improve muscle strength in adults and children with Barth syndrome weighing at least thirty kilograms. This approval is specific to the product, condition, and eligible population. [5] [6]
Approval has boundaries.
The approval relied on improved knee-extensor strength as an intermediate clinical endpoint. A confirmatory trial is required to establish that this translates into patient benefit. It does not establish an anti-aging treatment or a general performance enhancer. [5] [6]
Do not skip the safety context.
Injection-site reactions are common, and serious allergic reactions have been reported. A research-use label on a vial does not make it the FDA-approved product. This overview is education, not a recommendation to use a compound. [5]
Keep the claim inside the evidence.
The key takeaway: identify the model, examine the endpoint, and keep the claim within the evidence. This original AXON educational draft uses on-screen captions and conceptual diagrams. Scientific and legal review are pending. The transcript and linked sources accompany the video. [1] [2] [3] [4] [5] [6]
Sources and evidence
Primary studies and official U.S. regulatory sources support the claims cited above. This is a short educational overview, not a systematic review or specialist sign-off. Regulatory status is jurisdiction- and date-specific.
- Birk et al. · JASN · 2013 →Cardiolipin mechanism and rat renal ischemia model.
- Birk et al. · British Journal of Pharmacology · 2014 →Experiments in model membranes and isolated mitochondria.
- Karaa et al. · MMPOWER-3 · Neurology · 2023 →Randomized trial in primary mitochondrial myopathy; 218 participants.
- Thompson et al. · Genetics in Medicine · 2021 →Barth syndrome randomized crossover trial and open-label extension.
- FDA · Forzinity prescribing information · 2025 →Approved indication, accelerated approval, warnings, clinical studies.
- FDA · Approval announcement · 19 September 2025 →Specific approval and required confirmatory study.
